HK1157658A1 - Method for diagnosing cancers expressing the her2 receptor or its truncated variants - Google Patents

Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Info

Publication number
HK1157658A1
HK1157658A1 HK11112126.9A HK11112126A HK1157658A1 HK 1157658 A1 HK1157658 A1 HK 1157658A1 HK 11112126 A HK11112126 A HK 11112126A HK 1157658 A1 HK1157658 A1 HK 1157658A1
Authority
HK
Hong Kong
Prior art keywords
her2 receptor
cancers expressing
truncated variants
diagnosing cancers
diagnosing
Prior art date
Application number
HK11112126.9A
Other languages
English (en)
Inventor
López Joaquín Arribas
Kim Pedersen
Pier-Davide Angellini
Palau Josep Lluis Parra
Sirle Laos
Torres José Baselga
Original Assignee
Fundació Privada Inst De Recerca Hospital Univ
Fundació Privada Institució Catalana De Recerca I
Fundació Privada Inst D Investigació Oncol Gic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Inst De Recerca Hospital Univ, Fundació Privada Institució Catalana De Recerca I, Fundació Privada Inst D Investigació Oncol Gic filed Critical Fundació Privada Inst De Recerca Hospital Univ
Publication of HK1157658A1 publication Critical patent/HK1157658A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
HK11112126.9A 2008-06-02 2011-11-10 Method for diagnosing cancers expressing the her2 receptor or its truncated variants HK1157658A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200801652A ES2342646B1 (es) 2008-06-02 2008-06-02 Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
PCT/EP2009/056976 WO2010000565A1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Publications (1)

Publication Number Publication Date
HK1157658A1 true HK1157658A1 (en) 2012-07-06

Family

ID=40911029

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11112126.9A HK1157658A1 (en) 2008-06-02 2011-11-10 Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Country Status (21)

Country Link
US (1) US8389227B2 (zh)
EP (1) EP2293819B1 (zh)
JP (2) JP5753079B2 (zh)
KR (2) KR101785117B1 (zh)
CN (1) CN102202692B (zh)
AU (2) AU2009265921B2 (zh)
BR (1) BRPI0914969A2 (zh)
CA (1) CA2727365A1 (zh)
CY (1) CY1115798T1 (zh)
DK (1) DK2293819T3 (zh)
EA (1) EA025218B1 (zh)
ES (2) ES2342646B1 (zh)
HK (1) HK1157658A1 (zh)
HR (1) HRP20141158T1 (zh)
IL (1) IL209769A (zh)
MX (1) MX2010013419A (zh)
PL (1) PL2293819T3 (zh)
PT (1) PT2293819E (zh)
SI (1) SI2293819T1 (zh)
WO (1) WO2010000565A1 (zh)
ZA (1) ZA201009010B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002257132A1 (en) * 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
CA2749846C (en) 2009-01-15 2018-08-07 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-3
AU2010248884B2 (en) * 2009-05-14 2015-04-02 Nestec S.A. Biomarkers for determining sensitivity of breast cancer cells to HER2-targeted therapy
PT2330131E (pt) 2009-12-07 2015-01-14 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Anticorpos contra a variante truncada de her-2 ctf-611
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
CA2908391A1 (en) 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer
EP3825327A1 (en) 2014-03-11 2021-05-26 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
EP3604333B1 (en) 2014-03-11 2021-05-05 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions capable of specifically binding cd38
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
AU2016297920A1 (en) 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
WO2017196263A1 (en) * 2016-05-12 2017-11-16 Agency For Science, Technology And Research Anti-erbb-2 antibodies and uses thereof
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
ES2971981T3 (es) 2017-01-25 2024-06-10 Molecular Templates Inc Moléculas de reconocimiento de células que comprenden efectores de la subunidad A de la toxina Shiga desinmunizados y epítopos de células T CD8+
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
AU2020318781A1 (en) 2019-07-23 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Immune cells defective for SUV39H1
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0778848B1 (en) 1994-08-30 2007-12-26 University of Dundee Agents for inducing apoptosis and applications of said agents in therapy
WO1998006863A1 (en) * 1996-08-14 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A vector for polynucleotide vaccines
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
SI1187632T1 (sl) * 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
KR20110008112A (ko) * 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
SG177252A1 (en) * 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95

Also Published As

Publication number Publication date
AU2009265921A1 (en) 2010-01-07
DK2293819T3 (en) 2014-12-08
CY1115798T1 (el) 2017-01-25
CN102202692B (zh) 2014-03-12
EA025218B1 (ru) 2016-12-30
WO2010000565A1 (en) 2010-01-07
KR20110031187A (ko) 2011-03-24
EP2293819A1 (en) 2011-03-16
IL209769A0 (en) 2011-02-28
US8389227B2 (en) 2013-03-05
MX2010013419A (es) 2011-08-15
KR20160140974A (ko) 2016-12-07
KR101785117B1 (ko) 2017-11-07
AU2015202854A1 (en) 2015-06-18
IL209769A (en) 2016-04-21
BRPI0914969A2 (pt) 2015-10-20
JP2015214546A (ja) 2015-12-03
EP2293819B1 (en) 2014-09-03
US20090311262A1 (en) 2009-12-17
PL2293819T3 (pl) 2015-04-30
ZA201009010B (en) 2012-03-28
ES2342646A1 (es) 2010-07-09
CN102202692A (zh) 2011-09-28
JP2011525175A (ja) 2011-09-15
HRP20141158T1 (hr) 2015-02-13
ES2528132T3 (es) 2015-02-04
AU2009265921B2 (en) 2015-04-02
ES2342646B1 (es) 2011-04-26
PT2293819E (pt) 2014-12-09
JP5753079B2 (ja) 2015-07-22
SI2293819T1 (sl) 2015-01-30
EA201001874A1 (ru) 2011-08-30
CA2727365A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
HK1157658A1 (en) Method for diagnosing cancers expressing the her2 receptor or its truncated variants
HRP20151108T1 (en) Nogo receptor antagonists
SI2162382T1 (sl) Polnilni sistem
AP2011005719A0 (en) Anti-IGF antibodies.
HK1156638A1 (zh) 人α突觸核蛋白特異性自身抗體
GB201020970D0 (en) Early entry
IL212551A0 (en) Cxcr4 receptor compounds
EP2300828A4 (en) SCREENING SYSTEM FOR ANTIGENS
GB0821100D0 (en) Antibodies
GB0810457D0 (en) Gold system
HRP20141257T1 (en) Antibodies against her2 truncated variant ctf-611
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
GB0921999D0 (en) Early entry
ZA201100868B (en) Tungsten-based vacancy-keggin-type heteropolyanion for hydrocracking
EP2029771A4 (en) DIAGNOSTIC METHOD OF MYOPATHY
EP2312337A4 (en) TECHNIQUE FOR DETECTING CRANIAL NERVE DISEASE
ZA201006099B (en) Anti-tyrp1 antibodies
SI2307304T1 (sl) Polnilni sistem
ZA201007976B (en) Anti-pirb antibodies
GB0922083D0 (en) Early entry
GB0922210D0 (en) Car parkng apparatus
HK1151764A1 (en) Recess filling apparatus
GB0920030D0 (en) Early entry
GB0818356D0 (en) Antibodies
AU321195S (en) Birdcage roof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190604